|By Marketwired .||
|May 5, 2014 11:30 AM EDT||
NEW YORK, NY -- (Marketwired) -- 05/05/14 -- Kadmon Corporation, LLC, today announced the presentation of preclinical and clinical data from studies of KD025, the Company's Phase 2, orally bioavailable, potent and highly selective inhibitor of ROCK 2 (Rho-associated coiled-coiled kinase 2), used in models of autoimmune disease such as a collagen induced arthritis and lupus. The data were presented at the "T Helper Cell Differentiation and Cytokine Expression" session by Alexandra Zanin-Zhorov, Ph.D., Kadmon's Senior Director of Immunology, at "Immunology 2014," the Annual Meeting of the American Association of Immunologists (AAI), held May 2-6, 2014 in Pittsburgh, Pennsylvania. The poster, entitled "Selective ROCK2 inhibitor down-regulates pro-inflammatory T cell responses via shifting Th17/Treg balance," is available on the Kadmon website at www.kadmon.com.
"As we grow our understanding of the ROCK2 pathway and its critical role in regulating cell biology, immune response and immune homeostasis, we underscore the transformative potential of KD025 in broadly prevalent autoimmune diseases," said Samuel D. Waksal, Ph.D., Chairman and CEO of Kadmon. "We continue to make important progress in our clinical program for KD025, where we recently announced the initiation of a Phase 2a study in psoriasis, and expect to initiate additional Phase 2 studies in lupus nephritis and non-alcoholic steatohepatitis."
About Kadmon Corporation
Kadmon Corporation, LLC, is a global company built on a 21st-century paradigm for the translation of innovative science into treatment. The company currently offers products and services for the treatment and management of liver diseases, and is pioneering novel medicines in areas of serious disease, including oncology, immunology and infectious, neurodegenerative and ophthalmic diseases. Emphasizing emerging concepts in molecular biology and genomics, Kadmon is developing treatments and treatment combinations that target the metabolomics and signaling pathways associated with disease, with the goal of addressing some of today's most pressing areas of unmet medical need. For more information, visit www.kadmon.com.
This press release contains forward-looking statements. These forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Kadmon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Jul. 27, 2016 04:30 PM EDT Reads: 1,846
Jul. 27, 2016 04:30 PM EDT Reads: 163
Jul. 27, 2016 04:30 PM EDT Reads: 1,611
Jul. 27, 2016 04:18 PM EDT Reads: 131
Jul. 27, 2016 04:15 PM EDT Reads: 1,103
Jul. 27, 2016 04:00 PM EDT Reads: 1,048
Jul. 27, 2016 04:00 PM EDT Reads: 1,514
Jul. 27, 2016 04:00 PM EDT Reads: 1,733
Jul. 27, 2016 03:30 PM EDT Reads: 963
Jul. 27, 2016 01:45 PM EDT Reads: 432
Jul. 27, 2016 01:30 PM EDT Reads: 262
Jul. 27, 2016 01:00 PM EDT Reads: 1,187
Jul. 27, 2016 12:15 PM EDT Reads: 839
Jul. 27, 2016 12:00 PM EDT Reads: 1,036
Jul. 27, 2016 12:00 PM EDT Reads: 857